Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001437749-25-015478
Filing Date
2025-05-08
Accepted
2025-05-08 16:01:39
Documents
63
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q sava20250331_10q.htm   iXBRL 10-Q 835472
2 EXHIBIT 31.1 ex_798800.htm EX-31.1 13762
3 EXHIBIT 31.2 ex_798801.htm EX-31.2 13865
4 EXHIBIT 32.1 ex_798802.htm EX-32.1 7587
  Complete submission text file 0001437749-25-015478.txt   4888797

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA sava-20250331.xsd EX-101.SCH 49602
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE sava-20250331_cal.xml EX-101.CAL 30957
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE sava-20250331_def.xml EX-101.DEF 321815
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE sava-20250331_lab.xml EX-101.LAB 285592
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sava-20250331_pre.xml EX-101.PRE 348175
66 EXTRACTED XBRL INSTANCE DOCUMENT sava20250331_10q_htm.xml XML 662525
Mailing Address 6801 N CAPITAL OF TEXAS HIGHWAY BUILDING 1; SUITE 300 AUSTIN TX 78731
Business Address 6801 N CAPITAL OF TEXAS HIGHWAY BUILDING 1; SUITE 300 AUSTIN TX 78731 512-501-2444
CASSAVA SCIENCES INC (Filer) CIK: 0001069530 (see all company filings)

EIN.: 911911336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41905 | Film No.: 25925822
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)